A recovery-focused peptide
BPC-157 is a synthetic peptide made from 15 linked amino acids.
Lennox / Recovery careBPC-157 / 3 mg pictured
Recovery-focused peptide care
BPC-157.Move forward with recovery.
A 15-amino-acid peptide being studied for the biological processes involved in tissue repair, mobility, and recovery.
Lennox connects eligible adults with licensed providers to discuss whether provider-guided, pharmacy-dispensed BPC-157 may fit their health and recovery goals.
First month
$119/first month
Then, if prescribed
$179/month
- Licensed provider review
- Pharmacy dispensed if prescribed
- Personalized care
Provider evaluation required · Eligibility and results vary · Compounded drugs are not FDA-approved
Positive 8–6 advisory vote+Recovery focused+Provider guided+Pharmacy dispensed if prescribed+Positive 8–6 advisory vote+Recovery focused+Provider guided+Pharmacy dispensed if prescribed+
Why BPC-157
A new direction for recovery care.
BPC-157 is a peptide—a short chain of amino acids, the building blocks the body uses throughout its tissues.
Research interest centers on how BPC-157 may interact with repair signaling, new blood-vessel formation, fibroblast activity, and inflammatory pathways. These are promising areas of study for people focused on recovery, although individual benefits have not been established.
Multiple repair pathways
Preclinical studies point to signaling involved in blood flow, connective tissue, muscle, and the gut.
Personalized review
A licensed provider considers your goals, health history, and whether treatment is appropriate for you.
Potential benefits
Why people are interested.
These recovery areas are being actively studied. A provider can help you understand what the research may mean for your goals.
- 01
Tendon and ligament recovery
- 02
Muscle repair and return to activity
- 03
Joint comfort and mobility goals
- 04
Gut-lining resilience and repair
The science
Why research attention keeps growing.
BPC-157 has shown regenerative activity across numerous preclinical models. Early human pilot studies add interest and support the need for larger, well-controlled trials.
Connective-tissue support
Studies are exploring pathways associated with fibroblast activity and repair in tendons and other poorly vascularized tissues.
Blood-vessel response
Preclinical findings suggest activity involving VEGFR2, nitric oxide signaling, and angiogenesis—the formation of new blood vessels.
Inflammatory balance
Researchers are studying how BPC-157 interacts with inflammatory processes and endothelial, muscle, and gut-tissue repair.
Read the sources
Follow the science and the FDA process.
Review the July 2026 FDA advisory meeting and a peer-reviewed overview of BPC-157's potential in musculoskeletal recovery.
Provider-guided care
Make recovery personal.
Good peptide care starts with your health—not a one-size-fits-all protocol. Your provider reviews your goals, medical history, medications, and potential risks before deciding whether a prescription is appropriate.
- Discuss the recovery goal that matters most to you
- Review your health history, medicines, and allergies
- Understand the proposed formulation and how to use it
- Know what changes and side effects to monitor
- Stay connected to your care team with questions
For athletes
Provider evaluation required · Prescription not guaranteed · Individual response varies · BPC-157 and compounded drugs are not FDA-approved
BPC-157 is banned by WADA. Check the current rules for your sport.
Common questions
BPC-157 is a synthetic peptide made from 15 amino acids. It is being studied for activity involving tissue repair, blood-vessel formation, inflammatory signaling, and recovery.
On July 23, 2026, the committee voted 8–6, with one abstention, to recommend BPC-157-related substances for the 503A Bulks List. That is a positive step toward patient-specific pharmacy compounding, but the recommendation is non-binding and still requires FDA action.
Preclinical research is exploring tendon and ligament repair, muscle healing, angiogenesis, and gut-tissue resilience. Early human pilot studies are encouraging enough to support further research, but benefits are not yet established.
No. The recent advisory vote concerns pharmacy compounding; it is not FDA approval of BPC-157 as a drug. If prescribed, a provider should explain the evidence, potential risks, and what to expect.
Yes. Lennox is a telehealth platform for eligible adult patients—not a research-chemical seller. Treatment is considered by a licensed provider and, if prescribed, dispensed by a pharmacy for patient-specific use, subject to current law and availability.
Complete a private health review. A licensed provider will consider your recovery goals and health history, answer questions, and determine whether treatment is appropriate.
Your next step
Build your recovery plan.
First month$119Then $179/month if prescribed and continued.
Start private health review
- 01
Share your recovery goals
Tell us what you want to get back to, plus your health history, medicines, allergies, and past care.
- 02
Meet your provider
A licensed provider reviews the complete picture and answers your questions about BPC-157.
- 03
Move forward with support
If prescribed, receive clear instructions, pharmacy-dispensed treatment, and ongoing clinical guidance.
Private and provider guided
Ready to focus on recovery?
Start with a licensed provider who can understand your goals and help you make an informed decision.
Start private health review